Centre Hospitalier De Roubaix
- Address
- lock Available on a paid plan
Centre Hospitalier De Roubaix - Comprehensive Hematology and Multi-Specialty Research Center
Centre Hospitalier De Roubaix is a distinguished clinical research institution with extensive expertise in hematological malignancies and diverse therapeutic areas. The center demonstrates particular strength in acute leukemia research, participating in pivotal trials for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) in adult populations, including novel immunotherapeutic approaches and stem cell transplantation protocols.
- Hematological malignancies including acute leukemias, multiple myeloma, myeloproliferative neoplasms, and peripheral T-cell lymphomas with focus on advanced immunotherapies and transplantation strategies
- Inflammatory bowel disease research, particularly Crohn's disease with perianal complications and combination biologic therapies
- Critical care medicine including septic shock management and cardiovascular interventions
- Neurodegenerative disorders, pulmonary infections, and severe allergic asthma
The center's research portfolio reflects a commitment to evaluating cutting-edge immunotherapeutic agents such as blinatumomab, daratumumab, and isatuximab in hematologic cancers, while also investigating targeted therapies and precision medicine approaches. Their participation in multi-cohort randomized trials demonstrates capability in managing complex study designs across various medical specialties, from allogeneic hematopoietic stem cell transplantation in leukemia patients to novel anticoagulation strategies in myeloproliferative disorders and advanced biologic treatments for inflammatory conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 49 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier De Roubaix
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Controlled Trial Comparing Azathioprine and Methotrexate in Combination with Adalimumab for Endoscopic Response in Crohn's Disease Patients | Centre Hospitalier Universitaire Amiens Picardie | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 49 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 3 | Unknown | 2022-09-15 | 2026-03-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.